Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20526557 | 0.82 | CRHR1 (0.41) | HRH4CRHR1TSHRSMN1; SMN2KDM4E | |
| SCHEMBL20526544 | 0.72 | HRH4 (0.70) | HRH4CRHR1 | |
| SCHEMBL20529932 | 0.70 | HRH4 (0.77) | HRH4CRHR1 | |
| SCHEMBL20526542 | 0.67 | HRH4 (0.81) | HRH4 | |
| SCHEMBL3915273 | 0.66 | NOTUM (0.55) | TSHRSMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL4851010 | 0.65 | MAPK1 (0.41) | CYP1A2CYP2C19SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL8169741 | 0.65 | VCAM1 (0.60) | CYP1A2TSHRCYP2C19SMN1; SMN2KDM4E | |
| SCHEMBL18002653 | 0.63 | NOTUM (0.51) | TSHRSMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL22020324 | 0.63 | KDM4E (0.55) | TSHRSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL1763417 | 0.63 | VCAM1 (0.56) | CYP1A2TSHRCYP2C19SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172856-B2 | 2,4-diaminopyrimidine derivatives as histamine H4 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-08 | — | — | US | disclosed |
| US-20180289706-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-11 | — | — | US | disclosed |
| WO-2018187652-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172856-B2 | 2,4-diaminopyrimidine derivatives as histamine H4 modulators | HRH4, HRH3, HRH2 | HRH4 1/4885CRHR1 857/4885CYP1A2 3052/4885 |
| US-20180289706-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | HRH4, HRH3, HRH2 | HRH4 1/4885CRHR1 857/4885CYP1A2 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.